<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250340</url>
  </required_header>
  <id_info>
    <org_study_id>Diabetes and Oxidative Stress</org_study_id>
    <nct_id>NCT01250340</nct_id>
  </id_info>
  <brief_title>Type 2 Diabetes Mellitus and Atherosclerosis</brief_title>
  <official_title>Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In individuals with Type 2 Diabetes (T2D) it has been obtained an outstanding improvement in&#xD;
      the management of hyperglycemia, but it has not been achieved a similar result in the&#xD;
      reduction of the atherosclerotic syndrome. The comprehension of the mechanisms that link over&#xD;
      nutrition to inflammation and innate immune response can be important to understand the&#xD;
      relationship between insulin resistance, diabetes mellitus and endothelial dysfunction. It&#xD;
      will be investigated: 1) the role of Toll Like Receptors (TLR)s in the pathophysiology of T2D&#xD;
      and associated atherosclerosis; 2) the role of aspirin and nicotinamide adenine dinucleotide&#xD;
      phosphate (NADPH) oxidase inhibitor/s in the production of TxA2 and F2-isoprostanes in T2D&#xD;
      patients; 3)new biomarkers associated to Diabetes and atherosclerosis including markers of&#xD;
      endothelial dysfunction and cytokines.&#xD;
&#xD;
      It will be analyzed in isolated platelets from normal controls and/or diabetic patients the&#xD;
      production of TxA2, isoprostanes and pro-inflammatory/thrombotic cytokines using aspirin and&#xD;
      NADPHoxidase inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: prospective, controlled, randomized study. All eligible patients will be&#xD;
      randomly assigned in a 1:1 manner to receive aspirin or placebo.&#xD;
&#xD;
      In each recruited subjects we will do:&#xD;
&#xD;
        1. Anamnestic clinical information and Anthropometric measurements&#xD;
&#xD;
        2. Electrocardiogram, echocardiogram and ultrasound assessment of carotid intima-media&#xD;
           thickness (IMT) and flow-mediated dilatation (FMD)&#xD;
&#xD;
        3. Ankle-Brachial Index measurement (ABI)&#xD;
&#xD;
        4. blood samples from an antecubital vein after an overnight fast and urine samples at&#xD;
           baseline, after 3 days and after 30 days of aspirin (100 mg/day) administration.&#xD;
&#xD;
      Laboratory Methods: Blood samples will be immediately centrifuged at 2,000 rpm for 20 min at&#xD;
      4°C, and the supernatant was collected and stored at -80°C until measurement. All&#xD;
      measurements will be done blinded. Samples will be tested in duplicate, and those showing&#xD;
      values above the standard curve will be re-tested with appropriate dilutions.Analysis of&#xD;
      urinary and platelet isoprostane:Urinary PGF2α-III was measured by a previously described and&#xD;
      validated EIA assay method. Ten millilitre urine were extracted on a C-18 SPE column; the&#xD;
      purification was tested for recovery by adding a radioactive tracer (tritiated PGF2α-III)&#xD;
      (Cayman chemical). The eluates were dried under nitrogen, recovered with 1ml of buffer, and&#xD;
      assayed in a PGF2α-III specific EIA kit (Cayman chemical). Urinary PGF2α-III concentration&#xD;
      was corrected for recovery and creatinine excretion and expressed as pg/mg of creatinine. PRP&#xD;
      was then centrifuged 20 min at 800 g to concentrate platelets and the pellet was suspended in&#xD;
      Tyrode buffer to obtain a final platelet concentration of 5x108/mL. PGF2α-III content was&#xD;
      measured by a validated EIA assay method as previously described and expressed as pg/mg&#xD;
      platelet protein.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of isoprostanes after study drug administration.</measure>
    <time_frame>3 and 30 days</time_frame>
    <description>Mearuring levels of isoprostanes to understand if isoprostanes could play a crucial role in thrombus formation, independently from Aspirin mediated COX-1 inhibition, supporting their role in the phenomenon of the so call &quot;aspirin resistance&quot; in the setting of T2DM.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg/day for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 cp /day for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>100 mg/day for 30 days</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 cp day for 30 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes Mellitus (defined according to the criteria of the American Diabetes&#xD;
             Association)&#xD;
&#xD;
          -  Sign of a written informed consent to participate to the interventional study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Serious renal disorders (serum creatinine &gt;2.5 mg/dL)&#xD;
&#xD;
          -  History or evidence of previous major vascular events (myocardial infarction,&#xD;
             transient ischemic attack, stroke)&#xD;
&#xD;
          -  History of major bleeding&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Cancer or present or recent infections&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs, drugs interfering with cholesterol&#xD;
             metabolism, or vitamin supplements or antiplatelet drugs in the previous 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Violi</last_name>
    <role>Study Chair</role>
    <affiliation>Divisione di Prima Clinica Medica - Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Violi, Full Prof</last_name>
    <phone>+39-06-4461933</phone>
    <email>francesco.violi@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefania Basili, Ass Prof</last_name>
    <phone>+39-06-49974678</phone>
    <email>stefania.basili@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sapienza Università di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Violi, Full Prof</last_name>
      <phone>+39-06-4461933</phone>
      <email>francesco.violi@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Stefania Basili, Ass Prof</last_name>
      <phone>+39-06-49974678</phone>
      <email>stefania.basili@uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco Violi, full Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Violi</investigator_full_name>
    <investigator_title>Full professor of internal medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Isoprostanes</keyword>
  <keyword>Thromboxane</keyword>
  <keyword>Aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

